See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Activity of cefiderocol against non-fermenting gram-negative isolates collected from intensive care unit patients in US and European medical centers as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against non-fermenting gram-negative isolates collected from intensive care unit patients in US and European medical centers as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against resistant isolates collected from bloodstream infections during 2020 to 2024 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against resistant isolates collected from bloodstream infections during 2020 to 2024 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against Stenotrophomonas maltophilia clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014–2019) and SENTRY (2020–2024)
Activity of cefiderocol against Stenotrophomonas maltophilia clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014–2019) and SENTRY (2020–2024)
Activity of cefiderocol and comparator agents against European enterobacterales, including carbapenem-resistant isolates, from the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol and comparator agents against European enterobacterales, including carbapenem-resistant isolates, from the SENTRY antimicrobial surveillance program (2020–2024)
Categorisation of routine cefiderocol susceptibility by EUCAST zone diameter breakpoints has low predictability of clinical outcome for metallo-beta-lactamase-producing Enterobacterales
Categorisation of routine cefiderocol susceptibility by EUCAST zone diameter breakpoints has low predictability of clinical outcome for metallo-beta-lactamase-producing Enterobacterales
Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting gram-negative bacteria, including WHO priority pathogens, in China
Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting gram-negative bacteria, including WHO priority pathogens, in China
You Are Viewing Congress Locations
ASM Microbe 2026
ESPID 2026
AAN 2026
ESCMID 2026
CROI 2026
GSA 2025
APCCMI 2025
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
ISIRV 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
